Michael King
Stock Analyst at EF Hutton
(0.82)
# 3,987
Out of 5,093 analysts
109
Total ratings
35.25%
Success rate
-14.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $18.00 | +3,511.11% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.88 | +183.51% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.34 | +2,288.06% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.77 | +3,770.06% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $15.61 | +1,181.23% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.01 | +721.78% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $692.58 | +24.46% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $41.87 | -42.68% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $3.92 | +4,134.69% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $16.81 | +149.85% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $415.21 | -26.78% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $9.30 | +1,147.31% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.14 | +100.39% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $44.63 | -46.22% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $0.83 | +1,444,290.95% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $43.80 | +5.02% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $26.85 | +257.54% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.73 | +4,816.69% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $38.53 | -19.54% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $889.41 | -95.95% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $18.00
Upside: +3,511.11%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.88
Upside: +183.51%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.34
Upside: +2,288.06%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.77
Upside: +3,770.06%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $15.61
Upside: +1,181.23%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.01
Upside: +721.78%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $692.58
Upside: +24.46%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $41.87
Upside: -42.68%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.92
Upside: +4,134.69%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $16.81
Upside: +149.85%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $415.21
Upside: -26.78%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $9.30
Upside: +1,147.31%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.14
Upside: +100.39%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $44.63
Upside: -46.22%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $0.83
Upside: +1,444,290.95%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $43.80
Upside: +5.02%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $26.85
Upside: +257.54%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.73
Upside: +4,816.69%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $38.53
Upside: -19.54%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $889.41
Upside: -95.95%